Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner

Published:2023-11-23 Issue:1 Volume:51 Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Bao Yuhang¹,Wu Xiuxian¹,Kanematsu Akihiro¹,Kita Yuki²,Kobayashi Takashi²,Kakehi Yoshiyuki³,Yamamoto Shingo¹

Affiliation:

1. Department of Urology, Hyogo College of Medicine, Nishinomiya, Hyogo 663‑8501, Japan

2. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto 606‑8507, Japan

3. Department of Urology, Kagawa University Faculty of Medicine, Kagawa 761‑0793, Japan

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Reference40 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma;Albiges;J Clin Oncol,2012

3. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): Long-term follow-up results from an open-label, randomised, phase 3 trial;Motzer;Lancet Oncol,2022

4. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial;Motzer;Lancet Oncol,2019

5. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TRIAL-based combination therapies in cancers;International Immunopharmacology;2024-09

2. Current and future prospective of caspases targeting in cancer therapy;Caspases as Molecular Targets for Cancer Therapy;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3